Robert H Getzenberg

Publications (3)12.01 Total impact

• Article: Helping to address the over treatment of prostate cancer: tools to differentiate lethal and non-lethal phenotype in prostate cancer.

  Robert H Getzenberg, H Ballentine Carter
  Asian Journal of Andrology 04/2012; 14(3):347-8. · 1.52 Impact Factor
• Article: Eleventh Prouts Neck Meeting on Prostate Cancer: emerging strategies in prostate cancer therapy.

  Evan T Keller, David R Rowley, Scott A Tomlins, Charles G Drake, Philip W Kantoff, Kenneth J Pienta, James E Montie, H Ballentine Carter, Andrew M Hruszkewicz, Jorge Gomez, Suresh Mohla, Robert H Getzenberg
  Cancer Research 11/2007; 67(20):9613-5. · 7.86 Impact Factor
• Article: Androgens and prostate cancer: are the descriptors valid?

  Pradip Roy-Burman, Donald J Tindall, Diane M Robins, Norman M Greenberg, Mary J C Hendrix, Suresh Mohla, Robert H Getzenberg, John T Isaacs, Kenneth J Pienta
  [show abstract] [hide abstract]
  ABSTRACT: The term androgen-independent cancer has now become a misnomer. Given that the androgen receptor can be activated by even low androgen concentrations or via protein modifications or other protein-protein interactions, a growing prostate cancer has the chance of assuming an androgen depletion-independent state, without necessarily bypassing the androgen signaling processes. It is thus suggested that "androgen-independent (AI)" cancer should be more accurately termed "androgen depletion-independent (ADI)" cancer.
  Cancer biology & therapy 02/2005; 4(1):4-5. · 2.64 Impact Factor